Development of Sustainability Metrics and Targets and Disclosure of Results
First written in FY2023. . Latest entry: FY2026.
The whole theme swung hardest in 2021: 1 of 8 companies on the "Worse" side.
3 other companies' latest entry also says "Other".
- FY2026Update to sustainability indicators and resultsAnnual report
「Number of clinical trials initiated (target: 5 products by FY2027): 0 products (FY2023 to FY2025 total: 2 products); number of partnering agreements, public information only: 2; response rate for ongoing board effectiveness evaluations and implementation of improvement recommendations (target: 100%): 100%; number of internal reports handled: 17.」
The company disclosed FY2025 results including 0 clinical trials initiated, 2 publicly disclosed partnering agreements, a 100% response rate for the board effectiveness evaluation, and 17 internal reports. Human capital and environmental indicators were also updated. - FY2025Update to sustainability indicators and resultsAnnual report
「Number of clinical trials initiated (target: 5 products by FY2027): 2 products; reduction rate for CO2 emissions from industrial waste through recycling: 38.7%; number of partnering agreements, public information only: 1; findings by regulatory authorities in each country that could result in administrative action (target: 0): 0; product shortages and recalls due to product quality (target: 0): 0; ① average percentage of women among new graduates hired over the past 5 years: 43.7%; ② training expenditure per employee: ¥120,000.」
The company updated its FY2024 results for sustainability indicators, including 2 clinical trials initiated, a 38.7% reduction rate for waste-derived CO2 emissions, 1 publicly disclosed partnering agreement, 0 quality-related product shortages and recalls, a 43.7% proportion of women among new graduate hires, and training expenditure of ¥120,000 per employee. - FY2024Update to sustainability indicators and resultsAnnual report
「Number of clinical trials initiated (target: 5 products by FY2027): 1 product; number of partnering agreements, public information only: 2; findings by regulatory authorities in each country that could result in administrative action (target: 0): 0; product shortages and recalls due to product quality (target: 0): 0.」
As FY2023 results for its materiality indicators, the company disclosed 1 clinical trial initiated, 2 publicly disclosed partnering agreements, and 0 findings by regulatory authorities and 0 quality-related product shortages and recalls. It also added workforce-related indicators and a 100% response rate for the board effectiveness evaluation, among other items. - FY2023First statedAnnual report
「The Company is currently expanding its business, and detailed indicators and targets for its initiatives concerning "growth of people and organizations" are currently being formulated. GHG emissions (unit: t): Scope 1 3,315; Scope 2 5,266; Scope 3 79,466; Total 88,048」
For human capital, the company disclosed ¥125.082 million in workforce-related investment and, for the environment, disclosed GHG emissions as a consolidated metric for the first time. Detailed metrics and targets are under development.